McCormick & Company, Incorporated vs Tilray Brands Inc — how do they compare? McCormick & Company, Incorporated trades at $51.43 (market cap $13.96B), while Tilray Brands Inc trades at $4.21 (market cap $591.60M). The key difference: McCormick & Company, Incorporated is far larger — about 23.6× Tilray Brands Inc's market cap, and McCormick & Company, Incorporated pays a 3.7% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| MKC | TLRY | |
|---|---|---|
Market Cap | $13.96B | $591.60M |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $21.00 |
52-Week Low | $45.60 | $3.88 |
Enterprise Value | $18.57B | $758.73M |
Dividend Yield | 3.7% | — |
Signals from Pluang's Aura AI — not financial advice
McCormick & Company (MKC) trades at $51.90, down 0.35% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 8.64, net income margin of 21.91%, and consistent dividend growth. Recent Q1 2026 earnings beat expectations, while analyst consensus remains mixed with 11 buy, 17 hold, and 2 sell ratings. The pending $65 billion Unilever Foods merger and London listing plans represent significant corporate developments.
MKC presents a compelling value opportunity with attractive valuation metrics and stable profitability. The Unilever merger offers substantial growth potential but carries integration risks. Current technical weakness near support at $50-$51 creates a potential entry point for long-term investors seeking dividend income and merger upside.
TLRY trades at $4.30, down 4.44% today, reflecting ongoing investor skepticism despite record fiscal 2026 revenue of $915 million. The stock shows bearish technical signals with key support at $4.00, while fundamentals reveal significant challenges including negative net income margins (-13.26%) and consecutive earnings misses. Recent developments include strategic partnerships expansion in New York and California spirits markets and increased medical cannabis production capacity to 275 metric tonnes.
TLRY faces substantial execution risks with persistent losses and negative cash flow, though trading below book value (P/B 0.37) offers potential value. Analyst consensus remains cautious with 65% hold ratings, while regulatory progress in cannabis remains a key catalyst. The stock requires successful margin improvement and U.S. regulatory clarity for sustained recovery.
Trailing returns across standard periods
Latest headlines on both assets
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →